Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4792464 | 0.93 | TLR7 (0.48) | TLR8TLR7NUDT1ATMMEN1 | |
| SCHEMBL3168166 | 0.92 | TLR8 (0.46) | TLR8TLR7NUDT1ATMMEN1 | |
| SCHEMBL6099996 | 0.89 | TLR8 (0.49) | TLR8TLR7NUDT1MEN1KMT2A | |
| SCHEMBL18179115 | 0.88 | TLR7 (0.49) | TLR8TLR7NUDT1MEN1KMT2A | |
| SCHEMBL6718929 | 0.86 | TLR8 (0.47) | TLR8TLR7NUDT1MEN1KMT2A | |
| SCHEMBL4308938 | 0.86 | TLR8 (0.47) | TLR8TLR7NUDT1MEN1KMT2A | |
| SCHEMBL5616955 | 0.85 | TLR8 (0.47) | TLR8TLR7NUDT1MEN1KMT2A | |
| SCHEMBL4319537 | 0.85 | TLR8 (0.48) | TLR8TLR7NUDT1MEN1KMT2A | |
| SCHEMBL4313003 | 0.85 | TLR8 (0.46) | TLR8TLR7NUDT1MEN1KMT2A | |
| SCHEMBL6723768 | 0.85 | TLR8 (0.48) | TLR8TLR7NUDT1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1894244-A | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO (US) | 2007-01-10 | — | — | CN | disclosed |
| US-6989389-B2 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2006-01-24 | — | — | US | disclosed |
| US-6953804-B2 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-10-11 | — | — | US | disclosed |
| US-6916925-B1 | Dye labeled imidazoquinoline compounds | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-07-12 | — | — | US | disclosed |
| US-20040138248-A1 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-15 | — | — | US | disclosed |
| US-20040106640-A1 | Aryl ether substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. | 2004-06-03 | — | — | US | disclosed |
| EP-1228147-B1 | DYE LABELED IMIDAZOQUINOLINE COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6677348-B2 | INDUCE CYTOKINE BIOSYNTHESIS; ANTICARCINOGENIC AGENTS, VIRICIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-6670372-B2 | Immunomodulators, for inducing cytokine biosynthesis in animals, and in the treatment of viral and neoplastic diseases; imidazo(4,5-c) quinoline-4-amine compounds that have an ether containing substituent at the 1-position | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-30 | — | — | US | disclosed |
| US-20030212092-A1 | Aryl ether substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. | 2003-11-13 | — | — | US | disclosed |
| US-20030212091-A1 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-11-13 | — | — | US | disclosed |
| US-6630588-B2 | Imidazonaphthyridine, imidazopyridine and imidazoquinoline compounds that have immune response modulating activity and that contain a dye moiety, in particular, a fluorescent dye moiety, e.g., dipyrrometheneboron difluoride dyes | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-07 | — | — | US | disclosed |
| EP-1341789-A2 | ARYL ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20020120141-A1 | Dye labeled imidazoquinoline compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2002-08-29 | — | — | US | disclosed |
| EP-1228147-A1 | DYE LABELED IMIDAZOQUINOLINE COMPOUNDS | 3M Innovative Properties Company (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2002046189-A2 | ARYL ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| US-6376669-B1 | COMPLEXES | 3M INNOVATIVE PROPERTIES COMPANY | 2002-04-23 | — | — | US | disclosed |
| WO-2001034709-A1 | DYE LABELED IMIDAZOQUINOLINE COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120141-A1 | Dye labeled imidazoquinoline compounds | LY96, CD74, IFNAR1 | TLR8 126/4885TLR7 41/4885NUDT1 579/4885 |
| US-20040138248-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | TLR8 68/4885TLR7 20/4885NUDT1 1242/4885 |
| US-20040106640-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | TLR8 68/4885TLR7 20/4885NUDT1 1242/4885 |
| US-20030212092-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | TLR8 68/4885TLR7 20/4885NUDT1 1242/4885 |
| US-20030212091-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | TLR8 68/4885TLR7 20/4885NUDT1 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.